Patents by Inventor Ying-Ting Liu

Ying-Ting Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Naltrexone injectable sustained release formulation
    Patent number: 12201630
    Abstract: Provided is an injectable sustained release pharmaceutical formulation, including 3-acyl-naltrexone or a pharmaceutically acceptable salt thereof, a biocompatible organic solvent, and optionally a biocompatible polymeric material. Also provided is a method for treating opioid use disorder or alcoholism, including administering the injectable sustained release pharmaceutical formulation to a subject in need thereof. The pharmaceutical formulation provides a sustained release profile after one single injection, and the plasma levels of naltrexone in minipigs could provide a sustained release for 2 months.
    Type: Grant
    Filed: December 26, 2019
    Date of Patent: January 21, 2025
    Assignee: Alar Pharmaceuticals Inc.
    Inventors: Tong-Ho Lin, Yung-Shun Wen, Ying-Ting Liu, Zhi-Rong Wu
  • LONG-ACTING INJECTABLE FORMULATIONS OF KETAMINE PAMOATE SALTS
    Publication number: 20240099994
    Abstract: Provided are sustained-release pharmaceutical compositions including a ketamine pamoate salt and a pharmaceutically acceptable carrier thereof. The compositions include aqueous suspension, solution and matrix delivery system, which can provide sustained release for anesthesia, analgesia or treatment of central nervous system and anti-inflammatory diseases.
    Type: Application
    Filed: December 18, 2020
    Publication date: March 28, 2024
    Applicant: ALAR PHARMACEUTICALS INC.
    Inventors: Tong-Ho Lin, Yung-Shun Wen, Chai-Hsien Chen, Ying-Ting Liu, Rui-Zhi Hou, Zhi-Rong Wu
  • NALTREXONE INJECTABLE SUSTAINED RELEASE FORMULATION
    Publication number: 20220062277
    Abstract: Provided is an injectable sustained release pharmaceutical formulation, including 3-acyl-naltrexone or a pharmaceutically acceptable salt thereof, a biocompatible organic solvent, and optionally a biocompatible polymeric material. Also provided is a method for treating opioid use disorder or alcoholism, including administering the injectable sustained release pharmaceutical formulation to a subject in need thereof. The pharmaceutical formulation provides a sustained release profile after one single injection, and the plasma levels of naltrexone in minipigs could provide a sustained release for 2 months.
    Type: Application
    Filed: December 26, 2019
    Publication date: March 3, 2022
    Inventors: Tong-Ho Lin, Yung-Shun Wen, Ying-Ting Liu, Zhi-Rong Wu